The Hamburg-based health startup TimeTeller has secured Cologne-based capacura GmbH as a financier. The company is investing in technology that can be used to determine the optimal time to take medication, for example in cancer therapy.
TimeTeller in the running for the Deutsche Gründerpreis 2025
TimeTeller's patented diagnostic method is based on a saliva test, the results of which provide insights into the circadian rhythm, also known as the internal clock. This rhythm is unique to each individual and has a significant influence on metabolic processes, the functioning of the immune system, and the effectiveness of medication. TimeTeller is a spin-off of Charité Berlin and is now based at MSH Medical School Hamburg. Founded in 2023 by Prof. Dr. Angela Relógio (CEO) and Dr. Benjamin Dose (COO), the startup has already won a number of awards, including a German Startup Award, the Health Innovation Award, and at Female StartAperitivo. In 2025, it is nominated for the Deutsche Gründerpreis 2025 in the “StartUp” category. It will be awarded on 9 September in Berlin.
Venture capitalist capacura has been investing in startups in the education, health, and environment sectors since 2018. The financing of TimeTeller is intended to accelerate the market launch of the patented solution. The investment, the amount of which has been agreed to remain confidential, is part of a larger financing round that has not yet been completed. Private investors can participate in the future business success of TimeTeller by adding it to a portfolio managed by capacura and thereby acquiring profit participation rights.
